Pregabalin for chronic prostatitis
- PMID: 22895982
- DOI: 10.1002/14651858.CD009063.pub2
Pregabalin for chronic prostatitis
Abstract
Background: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a condition that is detrimental to the quality of life of men. Evidence suggests that it may have a neuropathic origin and therefore medications such as pregabalin might have a role in the controlling of symptoms.
Objectives: The primary objective was to compare pregabalin to other modalities of pain relief to alleviate men's symptoms of CP/CPPS.The secondary objective was to assess the safety and effectiveness of pregabalin to improve various individual symptoms consistent with CP/CPPS.
Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (1966 to May 2012), EMBASE (1980 to May 2012), CINAHL, clinicaltrials.gov, Google Scholar, and reference lists of articles and abstracts from conference proceedings, without language restriction for pregabalin treatment of Class III prostatitis and CP/CPPS.
Selection criteria: Randomized controlled trials (RCTs) comparing pregabalin to placebo or other types of analgesics for the management of patients with CP/CPPS were included. Patients with known causes of pain/discomfort were excluded.
Data collection and analysis: Only one RCT was included. The trial compared pregabalin to placebo for patients who had CP/CPPS.
Main results: For men who responded clinically (≥ 6-point improvement), there was no difference between the pregabalin (103/218; 47.2%) and placebo (38/106; 35.8%) arms (risk ratio (RR) 1.32; 95% CI 0.99 to 1.76). There was less pain with a higher point improvement in the pregabalin group compared to the placebo group (4.2 points versus 1.7 points, respectively; mean difference (MD) -2.3 points; 95% CI -4.0 to -0.7 points).Though 59% (191/324) of the patients developed side effects, no serious effects were experienced. There were significantly more neurologic side effects in the pregabalin group compared to the placebo group (38.5% (84/218) versus 22.6% (24/106), respectively; RR 1.7; 95% CI 1.15 to 2.51), and less pain in the pregabalin group than in the placebo group (17.4% (38/218) versus 33.3% (35/106), respectively; RR 0.53; 95% CI 0.36 to 0.78). However, no significant differences were seen between the pregabalin and placebo groups with regards to gastrointestinal disturbances (18.3% (40/218) versus 18.9% (20/106), respectively; RR 0.97; 95% CI 0.60 to 1.58), ocular/visual symptoms (6.9% (15/218) versus 2.8% (3/106), respectively; RR 2.43; 95% CI 0.72 to 8.22), and renal/genitourinary symptoms (5.5% (12/218) versus 1.9% (2/106), respectively; RR 3.03; 95% CI 0.67 to 13.79).
Authors' conclusions: There is evidence from one RCT that pregabalin does not improve CP/CPPS symptoms and causes adverse effects in a large percentage of men. However, research is required to assess further whether pregabalin has a role in patients with CP/CPPS for symptom control.
Similar articles
-
Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial.Arch Intern Med. 2010 Sep 27;170(17):1586-93. doi: 10.1001/archinternmed.2010.319. Arch Intern Med. 2010. PMID: 20876412 Free PMC article. Clinical Trial.
-
α-blockers, antibiotics and anti-inflammatories have a role in the management of chronic prostatitis/chronic pelvic pain syndrome.BJU Int. 2012 Oct;110(7):1014-22. doi: 10.1111/j.1464-410X.2012.11088.x. Epub 2012 Apr 3. BJU Int. 2012. PMID: 22471591 Review.
-
Anticonvulsants for fibromyalgia.Cochrane Database Syst Rev. 2013 Oct 16;(10):CD010782. doi: 10.1002/14651858.CD010782. Cochrane Database Syst Rev. 2013. Update in: Cochrane Database Syst Rev. 2017 Oct 09;10:CD010782. doi: 10.1002/14651858.CD010782.pub2. PMID: 24129853 Updated. Review.
-
Contemporary Management of Chronic Prostatitis/Chronic Pelvic Pain Syndrome.Eur Urol. 2016 Feb;69(2):286-97. doi: 10.1016/j.eururo.2015.08.061. Epub 2015 Sep 26. Eur Urol. 2016. PMID: 26411805 Review.
-
Management of chronic prostatitis/chronic pelvic pain syndrome: a systematic review and network meta-analysis.JAMA. 2011 Jan 5;305(1):78-86. doi: 10.1001/jama.2010.1913. JAMA. 2011. PMID: 21205969 Review.
Cited by
-
The methodological quality assessment of systematic reviews/meta-analyses of chronic prostatitis/chronic pelvic pain syndrome using AMSTAR2.BMC Med Res Methodol. 2023 Nov 27;23(1):281. doi: 10.1186/s12874-023-02095-0. BMC Med Res Methodol. 2023. PMID: 38012566 Free PMC article.
-
Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome.Cochrane Database Syst Rev. 2019 Oct 6;10(10):CD012552. doi: 10.1002/14651858.CD012552.pub2. Cochrane Database Syst Rev. 2019. PMID: 31587256 Free PMC article. Review.
-
Pelvic pain rehabilitation.Turk J Phys Med Rehabil. 2018 Nov 4;64(4):291-299. doi: 10.5606/tftrd.2018.3616. eCollection 2018 Dec. Turk J Phys Med Rehabil. 2018. PMID: 31453525 Free PMC article. Review.
-
Non-pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome.Cochrane Database Syst Rev. 2018 May 12;5(5):CD012551. doi: 10.1002/14651858.CD012551.pub3. Cochrane Database Syst Rev. 2018. PMID: 29757454 Free PMC article. Review.
-
Non-pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome.Cochrane Database Syst Rev. 2018 Jan 26;1(1):CD012551. doi: 10.1002/14651858.CD012551.pub2. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2018 May 12;5:CD012551. doi: 10.1002/14651858.CD012551.pub3. PMID: 29372565 Free PMC article. Updated. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous